Cronobacter sakazakii

Sterilex Reveals Patent-Pending Technology

Retrieved on: 
Wednesday, September 14, 2022
Cronobacter sakazakii, CEO, Listeria monocytogenes, Disinfectant, Campylobacter jejuni, Growth, Goal, Industry, EPA, Campylobacter, Sewage, Cronobacter

HUNT VALLEY, Md., Sept. 14, 2022 /PRNewswire/ -- Sterilex®, an industry leader in disinfection and microbial control, received EPA-approval on ProvaStride™, a new quaternary ammonium-free, powdered, non-food contact surface sanitizer and disinfectant designed to improve environmental sanitation on hard, non-porous surfaces where conditions favor microorganism growth.

Key Points: 
  • "Receiving EPA-approval is a big milestone as we bring ProvaStride to market," said Alex Josowitz, President and CEO at Sterilex.
  • ProvaStride is a sustainable alternative to Sterilex Ultra Step for customers and facilities with quat restrictions."
  • "Customers trust Sterilex to provide innovative solutions for microbial control and ProvaStride reinforces that commitment with a highly efficacious alternative to powdered quat sanitizers."
  • ProvaStride also provides customers with many of the same attributes they have come to expect from Sterilex Ultra Step, including:
    To learn more how Sterilex can help you reach your sustainability goals and learn more about ProvaStride, visit https://bit.ly/3DmEJLf

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, September 13, 2022
Securities Exchange Act of 1934, Safety, Advertising, NYSE, FDA, Food and Drug Administration, Infant, NEW, United, Similac, News, Investment, Cronobacter sakazakii, Laboratory, Bacteria, Company, Court, District court, GLOBE, Labour government, The Legal 500, Death, Fine chemical, Online gambling, Medical device, Cronobacter, Abbott Laboratories

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Wednesday, September 7, 2022
Safety, Securities Exchange Act of 1934, NYSE, District court, LLP, Cronobacter sakazakii, Death, United, Advertising, Infant, Court, Investment, NEW, GLOBE, Company, FDA, Labour government, News, The Legal 500, Similac, Food and Drug Administration, Laboratory, Bacteria, Fine chemical, Online gambling, Medical device, Abbott Laboratories, Cronobacter

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Abbott Laboratories Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Retrieved on: 
Thursday, September 1, 2022
Complaint, Safety, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cronobacter sakazakii, Lists of schools in England, Death, United, Food, Infant, OSHA, GLOBE, FDA, Company, News, Similac, Risk, Abbott Laboratories, Bacteria, Review, Risk management, Pharmaceutical industry, Cronobacter

LOS ANGELES, Sept. 01, 2022 (GLOBE NEWSWIRE) --  The Portnoy Law Firm advises Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) investors that a class action has been filed on behalf of investors. Abbott investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.   

Key Points: 
  • LOS ANGELES, Sept. 01, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Abbott Laboratories (Abbott or the Company) (NYSE: ABT) investors that a class action has been filed on behalf of investors.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • By early 2022, Abbott was responsible for producing 40 percent of the United States infant formula.
  • As a result of Defendants misrepresentations and omissions, Abbott common stock traded at artificially inflated prices during the Class Period.

INVESTOR ALERT: Abbott Laboratories Investors with Substantial Losses Have Opportunity to Lead the Abbott Laboratories Class Action Lawsuit - ABT

Retrieved on: 
Thursday, September 1, 2022
Class Action Lawsuit, Professional Services, Legal, Complaint, Safety, Securities Exchange Act of 1934, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Cronobacter sakazakii, Lists of schools in England, United, Food, SEC, Private Securities Litigation Reform Act, Infant, OSHA, Firefighter, Lawyer, Company, Enron, FDA, History, News, Similac, Abbott Laboratories, Laboratory, Bacteria, CASE, Tobacco, Fine chemical, Medical device, Cronobacter

The Abbott Laboratories class action lawsuit charges Abbott Laboratories and certain of its top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Abbott Laboratories class action lawsuit charges Abbott Laboratories and certain of its top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the Abbott Laboratories class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Abbott Laboratories class action lawsuit.
  • An investors ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Abbott Laboratories class action lawsuit.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Abbott Laboratories

Retrieved on: 
Wednesday, August 31, 2022
Legal, Professional Services, Complaint, Lists of action films, Safety, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cronobacter sakazakii, Lists of schools in England, Death, United, Class, BLB, Food, Infant, Court, OSHA, Firefighter, FDA, History, Company, Douglas v. U.S. District Court ex rel Talk America, News, Similac, Risk, Abbott Laboratories, Bacteria, Review, Security (finance), Risk management, Pharmaceutical industry, Cronobacter

BLB&G filed this action on behalf of its client, Pembroke Pines Firefighters & Police Officers Pension Fund, and the case is captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Abbott Laboratories, No.

Key Points: 
  • BLB&G filed this action on behalf of its client, Pembroke Pines Firefighters & Police Officers Pension Fund, and the case is captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Abbott Laboratories, No.
  • The complaint is based on an extensive investigation and a careful evaluation of the merits of this case.
  • By early 2022, Abbott was responsible for producing 40 percent of the United States infant formula.
  • As a result of Defendants misrepresentations and omissions, Abbott common stock traded at artificially inflated prices during the Class Period.

Albertsons Companies Voluntarily Recalls Select Store-Prepared Sandwiches Made With King’s Hawaiian® Pretzel Roll Products

Retrieved on: 
Sunday, August 14, 2022
Retail, Supermarket, Food, Beverage, PST, Multimedia, Jewel (supermarket), Andronico's, Cronobacter sakazakii, Clostridium botulinum, NYSE, Thumb, Randalls, ACI, Carrs-Safeway, Albertsons, Lucky, Community marketing, Kings, Safeway, Pak, Star Market, Shaw, ACME, Cronobacter, Eagle, Structured Product Labeling, Retail, Fungiculture, United, Vons

Albertsons Companies (NYSE: ACI), in cooperation with the voluntary recall of Kings Hawaiian pretzel roll products, is voluntarily recalling 18 store-prepared items made with Kings Hawaiian pretzel rolls.

Key Points: 
  • Albertsons Companies (NYSE: ACI), in cooperation with the voluntary recall of Kings Hawaiian pretzel roll products, is voluntarily recalling 18 store-prepared items made with Kings Hawaiian pretzel rolls.
  • The Kings Hawaiian recall is out of an abundance of caution due to its potential for microbial contamination, including from the organisms Cronobacter sakazakii and Clostridium botulinum.
  • The Kings Hawaiian recall announcement can be found here .
  • The supplier confirmed that no illnesses associated with Kings Hawaiian pretzel bread have been reported, and no pathogens have been found in any Kings Hawaiian products to date.

KING'S HAWAIIAN® ISSUES VOLUNTARY RECALL OF PRETZEL SLIDER BUNS, PRETZEL HAMBURGER BUNS AND PRETZEL BITES DUE TO THE RECALL OF AN INGREDIENT FROM SUPPLIER LYONS MAGNUS

Retrieved on: 
Friday, August 12, 2022
Safety, Cronobacter sakazakii, Clostridium botulinum, Cronobacter, Fast food

---------------------------------------------------------------------------------

Key Points: 
  • LOS ANGELES, Aug. 12, 2022 /PRNewswire/ -- King's Hawaiian is voluntarily recalling its Pretzel Slider Buns, Pretzel Hamburger Buns and Pretzel Bites products out of an abundance of caution following a recall of an ingredient used in the pretzel products from one of its suppliers, Lyons Magnus.
  • While no illnesses associated with King's Hawaiian pretzel bread have been reported, and no pathogens have been found in any King's Hawaiian products to date, the recall is being conducted to ensure consumer safety.
  • Consumers in possession of any King's Hawaiian Pretzel Slider Buns, King's Hawaiian Pretzel Hamburger Buns or King's Hawaiian Pretzel Bites should dispose of the product.
  • King's Hawaiian advises that consumers in possession of any King's Hawaiian Pretzel Slider Buns, King's Hawaiian Pretzel Hamburger Buns or King's Hawaiian Pretzel Bites should dispose of the product.

Lyons Magnus Voluntarily Recalls 53 Nutritional And Beverage Products Due To The Potential For Microbial Contamination

Retrieved on: 
Friday, July 29, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Urinary tract infection, Infection, Date, Cronobacter sakazakii, Vomiting, Immunodeficiency, Cronobacter, Fever, Food, Vaccine

FRESNO, Calif., July 28, 2022 /PRNewswire/ --Lyons Magnus LLC ("Lyons Magnus" or the "Company") today announcedthat it is voluntarily recalling nutritional and beverage products due to the potential for microbial contamination, including from the organism Cronobacter sakazakii.

Key Points: 
  • FRESNO, Calif., July 28, 2022 /PRNewswire/ --Lyons Magnus LLC ("Lyons Magnus" or the "Company") today announcedthat it is voluntarily recalling nutritional and beverage products due to the potential for microbial contamination, including from the organism Cronobacter sakazakii.
  • The list of recalled products does not include products intended for infants (i.e.
  • While infection related to Cronobacter sakazakii is rare, the common symptoms of illness could include fever, vomiting and urinary tract infection.
  • The 53 products were distributed nationally, while some products were limited in scope.

Abbott to Release Metabolic Nutrition Formulas

Retrieved on: 
Friday, April 29, 2022
Similac, FDA, Life, Salmonella, EAS (nutrition brand), Review, Anxiety, Cronobacter, Infant, Infection, Disease, Cronobacter sakazakii, Aluminium, Vaccine

Abbott has implemented corrective actions and is working with the FDA to address the situation before resuming operations at the Sturgis facility.

Key Points: 
  • Abbott has implemented corrective actions and is working with the FDA to address the situation before resuming operations at the Sturgis facility.
  • The recall did not include any of Abbott's metabolic nutrition formulas, and included only a single batch of Similac PM 60/40.
  • During the investigation, the metabolic nutrition formulas and all other batches of Similac PM 60/40 were placed on hold.
  • Abbott tests products prior to distribution, and no Abbott formula distributed to consumers tested positive for Cronobacter sakazakii or Salmonella.